- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05668013
En studie for å evaluere den langsiktige effekten av TEV-48574 ved moderat til alvorlig ulcerøs kolitt eller Crohns sykdom
En 24-ukers fase 2b langsiktig utvidelse, randomisert, dobbeltblind studie for å bestemme langsiktig farmakokinetikk, effekt, sikkerhet og tolerabilitet av TEV-48574 hos voksne pasienter med moderat til alvorlig ulcerøs kolitt eller Crohns sykdom hovedfasen av doserangeringsstudien (RELIEVE UCCD LTE)
The primary objective of the study is to evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 subcutaneous (sc) administered every 4 weeks (Q4W) in adult participants with inflammatory bowel disease (IBD).
Secondary objectives of the study are to:
- evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 sc administered Q4W in adult participants with IBD
- evaluate the safety and tolerability of 2 different maintenance dose regimens of TEV-48574 sc administered Q4W in adult participants with IBD
- evaluate the immunogenicity of 2 different maintenance dose regimens of TEV-48574 sc administered Q4W in adult participants with IBD
The total duration for a participant in the double-blind period only is 66 weeks; and for a participant in the open-label extension (OLE) period, up to an additional 268 weeks.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
-
Gorna Oryahovitsa, Bulgaria, 5100
- Multiprofile Hospital For Active Treatment St. Ivan Rilski Gorna Oriahovitsa EOOD
-
Sofia, Bulgaria, 1618
- 20th Diagnostic Consultancy Center, Sofia
-
Sofia, Bulgaria, 1784
- University Multiprofile Hospital for Active Treatment ACIBADEM City Clinic, Sofia
-
-
-
-
California
-
San Diego, California, Forente stater, 92103
- Clinical Applications Laboratories Inc
-
-
Florida
-
Kissimmee, Florida, Forente stater, 34741
- I.H.S. Health
-
Orlando, Florida, Forente stater, 32803
- Endoscopic Research, Inc.
-
Pinellas Park, Florida, Forente stater, 33781
- Gastro Florida
-
-
Illinois
-
Gurnee, Illinois, Forente stater, 60031
- Illinois Gastroenterology Group d/b/a GI Alliance - Gurnee
-
-
Indiana
-
New Albany, Indiana, Forente stater, 47150
- Gastroenterology Health Partners, PLLC
-
-
Kansas
-
Kansas City, Kansas, Forente stater, 66160
- University of Kansas Medical Center
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40218
- Gastroenterology Health Partners, PLLC - Central Louisville
-
-
Missouri
-
Liberty, Missouri, Forente stater, 64068
- BVL Clinical Research
-
St Louis, Missouri, Forente stater, 63110
- Washington University School of Medicine
-
-
Nevada
-
Las Vegas, Nevada, Forente stater, 89128.
- Vector Clinical Trials
-
-
Ohio
-
Beavercreek, Ohio, Forente stater, 45440
- Dayton Gastroenterology, LLC - Beavercreek
-
-
Texas
-
Harlingen, Texas, Forente stater, 78550
- Texas Digestive Specialists
-
Katy, Texas, Forente stater, 77494
- Gastro Health & Nutrition - Katy
-
San Antonio, Texas, Forente stater, 78229
- Gastroenterology Research of San Antonio LLC
-
Southlake, Texas, Forente stater, 76092
- Texas Digestive Disease Consultants, PLLC. dba GI Alliance - Southlake
-
Tyler, Texas, Forente stater, 75701
- Tyler Research Institute, LLC
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84124
- Care Access
-
-
-
-
-
Tbilisi, Georgia, 0119
- Israeli - Georgian Medical Research Clinic Healthycore LLC
-
Tbilisi, Georgia, 0180
- Malkhaz Katsiashvili Multiprofile Emergency Medicine Center LLC
-
-
-
-
-
Afula, Israel, 1834111
- HaEmek Medical Center
-
Beersheba, Israel, 8410101
- Soroka University Medical Center
-
-
-
-
-
Milan, Italia, 20132
- Hospital San Raffaele, IRCCS
-
Milan, Italia, 20157
- ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Polo University
-
Rozzano, Italia, 20089
- Clinical Institute Humanitas, IRCCS
-
-
-
-
-
Kashiwa, Japan, 277-0871
- Kokikai Tsujinaka Hospital Kashiwanoha, Department of Gastroenterology
-
Minato, Japan, 108-8642
- Kitasato University Kitasato Institute Hospital
-
Sakura, Japan, 285-8741
- Toho University Sakura Medical Center, Department of Gastroenterology
-
Shinjuku, Japan, 169-0073
- Tokyo Yamate Medical Center, Department of Gastroenterology
-
Toyama, Japan, 930-8550
- Toyama Prefectural Central Hospital, Department of Internal Medicine, Gastroenterology
-
-
-
-
-
Lorenskog, Norge, 1478
- Akershus University Hospital
-
-
-
-
-
Bydgoszcz, Polen, 85-794
- CLINSANTE Clinical Research Centre Ewa Galczak-Nowak, Malgorzata Trzaska
-
Częstochowa, Polen, 42-202
- Synexus Polska Sp. Z o.o. Branch in Czestochowa
-
Elblag, Polen, 82-300
- St. John Paul 2nd Municipal Hospital in Elblag, Department of Internal Diseases
-
Gdansk, Polen, 80-382
- Synexus Polska Sp. z o.o. Branch in Gdansk
-
Katowice, Polen, 40-040
- Synexus Polska Sp. z o.o. Branch in Katowice
-
Krakow, Polen, 31-506
- Topolowa Medicenter
-
Krakow, Polen, 31-156
- Landa Specialist Doctor's Offices
-
Krakow, Polen, 30-363
- PLEJADY Medical Centre
-
Kłodzko, Polen, 57-300
- GLOBE Clinical Research
-
Lodz, Polen, 90-752
- IP Clinic
-
Nowy Targ, Polen, 34-400
- Non-Public Healthcare Facility Allmedica Clinical Trials
-
Poznan, Polen, 60-702
- Synexus Polska Sp. z o.o. Branch in Poznan
-
Poznan, Polen, 54-144
- EMC Medical Institute Joint Stock Company, Certus Private Healthcare Facility Hospital No. 1
-
Poznan, Polen, 54-144
- EMC Medical Institute Joint Stock Company, Penta Hospitals Clinics, Wroclaw Wejherowska
-
Poznan, Polen, 60-529
- SOLUMED Medical Center
-
Sopot, Polen, 81-756
- Endoskopia Sp. z o.o. (LLC)
-
Staszów, Polen, 28-200
- New health-CK, Kieltucki and partners g.p.
-
Szczecin, Polen, 71-685
- SONOMED
-
Szczecin, Polen, 71-434
- TWOJA PRZYCHODNIA Medical Centre of Szczecin
-
Torun, Polen, 87-100
- Torun Gastrology Centre Gastromed
-
Wadowice, Polen, 34-100
- NZOZ Formed
-
Warsaw, Polen, 02-672
- Synexus Polska Sp. z o.o. Branch in Warsaw
-
Warsaw, Polen, 04-501
- WIP Warsaw IBD Point Profesor Kierkus
-
Warsaw, Polen, 00-189
- MDM Healthcare Centre
-
Warsaw, Polen, 02-786
- WSD Medi
-
Wroclaw, Polen, 52-416
- Medical Centre Oporow
-
Wroclaw, Polen, 53-673
- FutureMeds Wroclaw
-
Wroclaw, Polen, 53-149
- VISTAMED
-
Wroclaw, Polen, 53-611
- Melita Medical Medical Center
-
Zamość, Polen, 22-400
- ETG Zamosc
-
Łęczna, Polen, 21-010
- Independent Public Healthcare Center in Leczna
-
-
-
-
-
Bardejov, Slovakia, 085 01
- ALIAN, s.r.o.
-
Bratislava, Slovakia, 811 09
- Cliniq, s.r.o.
-
Košice, Slovakia, 040 13
- Endomed, s.r.o.
-
Prešov, Slovakia, 080 01
- GASTRO I, s.r.o.
-
Prešov, Slovakia, 080 01
- Gastro LM s.r.o.
-
-
-
-
-
Huelva, Spania, 21005
- Juan Ramon Jimenez Hospital
-
Santiago de Compostela, Spania, 15702
- Gaias Santiago Clinic
-
Valencia, Spania, 46026
- University and Polytechnic Hospital La Fe
-
-
-
-
-
London, Storbritannia, SE1 9RT
- Guy's Hospital
-
-
-
-
-
Brno, Tsjekkia, 615 00
- Military Hospital Brno
-
Klatovy, Tsjekkia, 339 01
- GASTRO JeKa s.r.o.
-
Slaný, Tsjekkia, 274 01
- Hospital Slany
-
-
-
-
-
Kiel, Tyskland, 24105
- University Hospital Schleswig-Holstein
-
Tübingen, Tyskland, 72076
- University Hospital Tuebingen
-
Ulm, Tyskland, 89081
- University Hospital Ulm
-
Wipperfürth, Tyskland, 51688
- Group Practice Jakobeit
-
-
-
-
-
Chernivtsi, Ukraina, 58002
- Regional Communal Noncommercial Enterprise: Chernivtsi Regional Clinical Hospital, Department of Gastroenterology
-
Ivano-Frankivsk, Ukraina, 76008
- Communal Non-Profit Enterprise Regional Clinical Hospital of Ivano-Frankivsk Regional Council
-
Lviv, Ukraina, 79000
- University Hospital branch of State Non-Profit Enterprise Danylo Halytsky Lviv National Medical University
-
Lviv, Ukraina, 79010
- Municipal Non-Profit Enterprise Lviv Territorial Medical Union Multidisciplinary Clinical Hospital of Emergency and Intensive Ca
-
Lviv, Ukraina, 79010
- University Hospital of the State Non-Profit Company Danylo Halytsky Lviv National Medical University, Clinic of Surgery, Proctol
-
Uzhhorod, Ukraina, 88018
- Public Non-Profit Enterprise Andrii Novak Zakarpattia Regional Clinical Hospital under Zakarpattia Regional Council
-
Vinnytsia, Ukraina, 21018
- Municipal Non-Profit Enterprise Vinnytsia Regional Clinical Hospital named after M.I. Pirogov Vinnytsia Regional Council, Depart
-
Vinnytsia, Ukraina, 21018
- National Pirogov Memorial Medical University, University Clinic of Vinnytsia National Pirogov Memorial Medical University (Treat
-
-
-
-
-
Budapest, Ungarn, H-1033
- Clinexpert Ltd. Budapest
-
Budapest, Ungarn, 1085
- Semmelweis University, Department of Internal Medicine and Hematology
-
Vác, Ungarn, H-2600
- Javorszky Odon Hospital Vac
-
-
-
-
-
Vienna, Østerrike, 1090
- Medical University Vienna
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Maintenance Period- Participants who achieved clinical response and/or clinical remission at week 14 of TV48574-IMM-20036 (the 14-week DRF study) or in the re-induction period of this study.
- Re-induction- Participants who did not achieve clinical response and/or clinical remission at week 14 of the TV48574-IMM-20036 DRF study
NOTE- Additional criteria may apply, please contact the investigator for more information
Exclusion Criteria:
- Participants who discontinued the TV48574-IMM-20036 study before scheduled week 14 visit (any reason including lack of efficacy, safety, or personal reasons)
- Participant has any concomitant conditions or treatments that could interfere with study conduct, influence the interpretation of study observations/results, or put the participant at increased risk during the study as judged by the investigator and/or the clinical study physician.
- Participant anticipates requiring major surgery during this study.
- Participant is currently pregnant or lactating or is planning to become pregnant or to lactate during the study or for at least 50 days after administration of the last dose of IMP in case of early termination. Any woman becoming pregnant during the study will be withdrawn from the study.
NOTE- Additional criteria apply, please contact the investigator for more information
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: TEV-48574 Dose Regimen A for Ulcerative Colitis (UC)
Administered by subcutaneous infusion for participants with UC |
Subcutaneous (sc) administration using a commercial sc infusion system
Andre navn:
|
|
Eksperimentell: TEV-48574 Dose Regimen A for Crohn's Disease (CD)
Administered by subcutaneous infusion for participants with CD |
Subcutaneous (sc) administration using a commercial sc infusion system
Andre navn:
|
|
Eksperimentell: TEV-48574 Dose Regimen B for Ulcerative Colitis (UC)
Administered by subcutaneous infusion for participants with UC |
Subcutaneous (sc) administration using a commercial sc infusion system
Andre navn:
|
|
Eksperimentell: TEV-48574 Dose Regimen B for Crohn's Disease (CD)
Administered by subcutaneous infusion for participants with CD |
Subcutaneous (sc) administration using a commercial sc infusion system
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants with moderate to severe ulcerative colitis (UC) who show clinical remission as defined by the Mayo score
Tidsramme: Week 44
|
Clinical remission based on modified (9-point rectal bleeding, stool frequency, and endoscopy) Mayo score of ≤2 points, which is defined by:
|
Week 44
|
|
Number of participants with moderate to severe Crohn's disease (CD) who show an endoscopic response as defined by the Endoscopic Score for Crohn's Disease
Tidsramme: Week 44
|
Endoscopic response, defined as a decrease in Simple Endoscopic Score for Crohn's Disease (SES-CD) of at least 50% from DRF study baseline at week 44 in participants with CD |
Week 44
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Antall ADA-positive deltakere med tilstedeværelse av nøytraliserende ADA
Tidsramme: Uke 0, 4, 8, 16, 28, 44 og 48
|
Uke 0, 4, 8, 16, 28, 44 og 48
|
|
|
Antall deltakere som sluttet å ta undersøkelsesmidlet (IMP) på grunn av bivirkninger i den dobbeltblinde perioden
Tidsramme: Frem til uke 48
|
Frem til uke 48
|
|
|
Antall deltakere som sluttet å ta forsøkslegemidlet (IMP) på grunn av uønskede hendelser i den åpne perioden (OL)
Tidsramme: Inntil 5 år etter start av OL-periode
|
Inntil 5 år etter start av OL-periode
|
|
|
Antall deltakere med behandlingsfremvoksende antistoffantistoffer (ADA)
Tidsramme: Uke 0, 4, 8, 16, 28, 44 og 48
|
Uke 0, 4, 8, 16, 28, 44 og 48
|
|
|
Number of participants with moderate to severe UC with a clinical response as defined by Mayo score
Tidsramme: Week 44
|
Clinical response at week 44, defined as a decrease from baseline in the modified (9-point rectal bleeding, stool frequency, and endoscopy) Mayo score of at least 2 points AND at least a 30% reduction from DRF baseline with either a decrease in rectal bleeding subscore of at least 1 or an absolute rectal bleeding subscore of less than or equal to 1 |
Week 44
|
|
Number of participants with moderate to severe UC with Endoscopic improvement as defined by Mayo score
Tidsramme: Week 44
|
Endoscopic improvement defined as a Mayo endoscopic subscore of 0 or 1 |
Week 44
|
|
Number of participants with moderate to severe UC in Endoscopic remission as defined by Mayo score
Tidsramme: Week 44
|
Endoscopic remission defined as a Mayo endoscopic subscore of 0 |
Week 44
|
|
Number of participants with moderate to severe UC with Corticosteroid-free clinical remission based on the modified Mayo score
Tidsramme: Week 44
|
Defined by clinical remission and corticosteroid-free for ≥12 weeks preceding week 44 |
Week 44
|
|
Number of participants with moderate to severe CD with a clinical response based on Crohn's Disease Activity Index
Tidsramme: Week 44
|
Clinical response defined as a ≥100-point decrease from DRF baseline Crohn's Disease Activity Index (CDAI) score |
Week 44
|
|
Number of participants with moderate to severe CD in clinical remission as defined by CDAI score
Tidsramme: Week 44
|
Clinical remission defined as a CDAI score less than 150 |
Week 44
|
|
Number of participants with moderate to severe CD with Corticosteroid-free endoscopic response based on SES-CD
Tidsramme: Week 44
|
Defined by endoscopic response and corticosteroid-free for ≥12 weeks preceding week 44 |
Week 44
|
|
Number of participants with moderate to severe CD with Corticosteroid-free clinical remission based on CDAI
Tidsramme: Week 44
|
Defined by a CDAI score of <150 points and corticosteroid-free for ≥12 weeks preceding week 44 |
Week 44
|
|
Number of participants who experience adverse events in the double-blind period
Tidsramme: Up to Week 48
|
Adverse events can include any of the following clinically significant changes in clinical laboratory test results (serum chemistry, hematology, and urinalysis), vital signs measurements (blood pressure, pulse rate, body temperature, and respiratory rate), 12-lead electrocardiogram (ECG), and injection site reactions. |
Up to Week 48
|
|
Number of participants who experience adverse events in the open-label (OL) period
Tidsramme: Up to 5 years after start of OL period
|
Adverse events can include any of the following clinically significant changes in clinical laboratory test results (serum chemistry, hematology, and urinalysis), vital signs measurements (blood pressure, pulse rate, body temperature, and respiratory rate), 12-lead electrocardiogram (ECG), and injection site reactions. |
Up to 5 years after start of OL period
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Studieleder: Teva Medical Expert, MD, Teva Branded Pharmaceutical Products R&D LLC
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- TV48574-IMM-20038
- 2022-002593-89 (Registeridentifikator: EudraCT (EU))
- 2024-515027-11-00 (Registeridentifikator: CTIS (EU))
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be assessed for scientific merit, product approval status, and conflicts of interest. If the request is approved, patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .